CAMCEVI

Exhibitor: FORESEE PHARMACEUTICALS CO., LTD.

Booth No: L226

Characteristic

CAMCEVI (leuprolide) is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer. Designed and developed through Foresee's pioneering Stabilized Injectable Formulation (SIF) technologies, CAMCEVI is the first successfully commercialized product, as well as the first leuprolide product that comes as a prefilled, ready-to-use long-acting depot injection requiring no mixing. CAMCEVI overcomes the requirement of manual reconstitution – an obstacle faced by the previous marketed leuprolide products, which can lead to handling inconvenience and potential risks of handing errors.
CAMCEVI 42 mg (6-month dosage), for the treatment of advanced prostate cancer, is now approved in the U.S., Canada, EU, and Taiwan and launched in the U.S. in 2022.